Trial · NCT02639182
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review | AGS-16C3F | 2.9 | 95% Confidence Interval 2.0 to 4.0 | Months | |
| Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review | Axitinib | 5.7 | 95% Confidence Interval 5.3 to 9.1 | Months | |
| PFS Per RECIST v1.1 as Assessed by Blinded Central Radiology Assessment | AGS-16C3F | 3.5 | 95% Confidence Interval 2.1 to 3.8 | Months | |
| PFS Per RECIST v1.1 as Assessed by Blinded Central Radiology Assessment | Axitinib | 4.5 | 95% Confidence Interval 3.5 to 7.6 | Months | |
| Objective Response Rate (ORR) Based on the Investigator's Radiographic Assessment | AGS-16C3F | 7.5 | 95% Confidence Interval 2.5 to 16.6 | Percentage of Participants | |
| Objective Response Rate (ORR) Based on the Investigator's Radiographic Assessment | Axitinib | 18.2 | 95% Confidence Interval 9.8 to 29.6 | Percentage of Participants | |
| Duration of Response (DOR) Based on the Investigator's Radiographic Assessment | AGS-16C3F | 6.8 | 95% Confidence Interval 3.8 to 18.4 | Months | |
| Duration of Response (DOR) Based on the Investigator's Radiographic Assessment | Axitinib | 6.7 | 95% Confidence Interval 1.8 to 9.2 | Months | |
| Overall Survival (OS) | AGS-16C3F | 13.1 | 95% Confidence Interval 10.1 to 23.0 | Months | |
| Overall Survival (OS) | Axitinib | 15.5 | 95% Confidence Interval 12.7 to 21.6 | Months | |
| Disease Control Rate (DCR) Based on the Investigator's Radiographic Assessment | AGS-16C3F | 13.4 | 95% Confidence Interval 6.3 to 24.0 | Percentage of Participants | |
| Disease Control Rate (DCR) Based on the Investigator's Radiographic Assessment | Axitinib | 22.7 | 95% Confidence Interval 13.3 to 34.7 | Percentage of Participants | |
| Number of Participants With Adverse Events | AGS-16C3F | 65 | Participants | ||
| Number of Participants With Adverse Events | Axitinib | 64 | Participants | ||
| Maximum Observed Serum Concentration (Cmax) of Antibody Drug Conjugate (ADC) | AGS-16C3F | Cycle 1 | 52.21 | Standard Deviation 58.407 | Microgram per Milliliter (μg/mL) |
| Maximum Observed Serum Concentration (Cmax) of Antibody Drug Conjugate (ADC) | AGS-16C3F | Cycle 4 | 48.66 | Standard Deviation 38.820 | Microgram per Milliliter (μg/mL) |
| Mean Predose Serum Concentration (Ctrough) of ADC | AGS-16C3F | Cycle 2 | 3429.39 | Standard Deviation 1402.334 | Nanogram per Milliliter (ng/mL) |
| Mean Predose Serum Concentration (Ctrough) of ADC | AGS-16C3F | Cycle 3 | 5194.21 | Standard Deviation 3602.012 | Nanogram per Milliliter (ng/mL) |
| Mean Predose Serum Concentration (Ctrough) of ADC | AGS-16C3F | Cycle 4 | 7731.38 | Standard Deviation 11171.906 | Nanogram per Milliliter (ng/mL) |
| Mean Predose Serum Concentration (Ctrough) of ADC | AGS-16C3F | Cycle 6 | 5695.13 | Standard Deviation 3899.222 | Nanogram per Milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02639182/results